Form 10-Q Protalix BioTherapeutics For: Jun 30

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Form 10-Q Protalix BioTherapeutics For: Jun 30

Protalix BioTherapeutics (PLX) Issues Positive Update on PRX-102 Phase I/II; Improvements of Stabilization Noted

August 10, 2016 7:44 AM EDT

Protalix BioTherapeutics, Inc. (NYSE: PLX) announced additional positive data from its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. PRX-102 is a recombinant, plant cell expressed, pegylated, modified version of the human alpha-Galactosidase-A enzyme.

We are pleased to announce additional positive results from our phase I/II Fabry clinical trial, said Moshe Manor, Protalixs President and Chief Executive Officer. The efficacy results seen to date continue to be very strong with improvements or stabilization in efficacy demonstrated across all disease parameters giving us confidence in our phase III head-to-head study... More

Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share

August 8, 2016 4:56 PM EDT

Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), versus ($0.05) reported last year. Revenue for the quarter came in at $1.77 million, versus $1.34 million reported last year.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.

... More